Argus
•
Oct 14, 2026
ROIV: Lowering target price to $35.00
Summary
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: BridgeBio Pharma, Inc.
Oct 28, 2026
•
BBIO
KRYS: Lowering target price to $353.00
Oct 28, 2026
•
KRYS
PTGX: Raising target price to $148.00
Oct 28, 2026
•
PTGX
Weekly Stock List
Oct 26, 2026
•
TMO, CRL, PFE, IQV, DHR
KRYS: Raising target price to $358.00
Oct 21, 2026
•
KRYS
